Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-14 6:38 pm Sale |
2024-12-31 | 13G | GlycoMimetics, Inc. GLYC |
RA Capital Management, L.P. | 0 0.000% |
-6,383,000 (Position Closed) |
Filing History |
| 2024-11-27 2:22 pm Purchase |
2024-11-25 | 13G | GlycoMimetics, Inc. GLYC |
Logos Global Management LP | 5,000,000 7.800% |
5,000,000 (New Position) |
Filing History |
| 2024-11-12 4:30 pm Sale |
2024-09-30 | 13G | GlycoMimetics, Inc. GLYC |
Invus Public Equities, L.P. | 1,965,114 3.000% |
-3,323,394 (-62.84%) |
Filing History |
| 2024-11-06 5:41 pm Purchase |
2024-10-30 | 13G | GlycoMimetics, Inc. GLYC |
RA Capital Management, L.P. | 6,383,000 9.900% |
6,383,000 (New Position) |
Filing History |
| 2024-11-04 4:26 pm Purchase |
2024-10-29 | 13D | GlycoMimetics, Inc. GLYC |
Adage Capital Management L.P. | 5,091,231 7.900% |
5,091,231 (New Position) |
Filing History |
| 2024-11-04 2:01 pm Sale |
2024-10-30 | 13G | GlycoMimetics, Inc. GLYC |
Weinstein Benjamin | 50,000 0.100% |
-3,353,931 (-98.53%) |
Filing History |
| 2024-08-15 5:01 pm Sale |
2024-08-13 | 13G | GlycoMimetics, Inc. GLYC |
Invus Public Equities, L.P. | 5,288,508 8.200% |
-3,300,556 (-38.43%) |
Filing History |
| 2024-08-14 4:13 pm Purchase |
2024-08-09 | 13G | GlycoMimetics, Inc. GLYC |
Weinstein Benjamin | 3,403,931 5.300% |
3,403,931 (New Position) |
Filing History |
| 2024-07-29 7:24 pm Purchase |
2024-07-25 | 13G | GlycoMimetics, Inc. GLYC |
Invus Public Equities, L.P. | 8,589,064 13.300% |
8,589,064 (New Position) |
Filing History |
| 2024-05-08 5:06 pm Sale |
2024-05-06 | 13D | GlycoMimetics, Inc. GLYC |
New Enterprise Associates 10, Limited Partnership | 2,181,892 5.000% |
-1,826,085 (-45.56%) |
Filing History |
| 2024-02-29 7:28 pm Sale |
2024-02-06 | 13D | GlycoMimetics, Inc. GLYC |
New Enterprise Associates 10, Limited Partnership | 4,007,977 6.200% |
-713,899 (-15.12%) |
Filing History |
| 2024-02-12 4:48 pm Sale |
2024-02-06 | 13D | GlycoMimetics, Inc. GLYC |
New Enterprise Associates 10, Limited Partnership | 4,721,876 7.300% |
-245,654 (-4.95%) |
Filing History |
| 2024-02-09 5:03 pm Purchase |
2023-12-31 | 13G | GlycoMimetics, Inc. GLYC |
Artal Participations S.a r.l | 8,589,064 13.300% |
2,015,266 (+30.66%) |
Filing History |
| 2024-01-29 4:31 pm Unchanged |
2023-03-29 | 13G | GlycoMimetics, Inc. GLYC |
BIOTECHNOLOGY VALUE FUND L P | 9,544,262 14.800% |
0 (Unchanged) |
Filing History |
| 2023-02-13 5:18 pm Purchase |
2023-02-09 | 13G | GlycoMimetics, Inc. GLYC |
Artal Participations S.a r.l | 6,573,798 12.500% |
6,573,798 (New Position) |
Filing History |
| 2023-02-10 5:23 pm Sale |
2023-01-26 | 13D | GlycoMimetics, Inc. GLYC |
New Enterprise Associates 10, Limited Partnership | 4,967,530 9.500% |
-4,143,797 (-45.48%) |
Filing History |
| 2022-02-10 08:11 am Sale |
2021-12-31 | 13G | GlycoMimetics, Inc. GLYC |
The Vanguard Group | 2,238,553 4.330% |
-330,686 (-12.87%) |
Filing History |
| 2021-07-12 08:29 am Sale |
2021-06-30 | 13G | GlycoMimetics, Inc. GLYC |
BlackRock Inc. BLK |
886,148 1.700% |
-1,730,329 (-66.13%) |
Filing History |
| 2021-02-16 08:24 am Sale |
2020-12-31 | 13G | GlycoMimetics, Inc. GLYC |
Camber Capital Management LP | 2,200,000 4.600% |
-1,300,000 (-37.14%) |
Filing History |
| 2021-02-12 3:42 pm Sale |
2020-12-31 | 13G | GlycoMimetics, Inc. GLYC |
EcoR1 Capital LLC | 0 0.000% |
-2,909,800 (Position Closed) |
Filing History |